Results 271 to 280 of about 780,677 (341)

The structure of vulnerabilities for social anxiety disorder

, 2017
Thomas L. Rodebaugh, Cheri A. Levinson, Julia Langer, Justin W. Weeks, Richard G. Heimberg, Patrick J. Brown, Andrew R. Menatti, Franklin R. Schneier, Carlos Blanco, Michael R. Liebowitz   +9 more
openalex   +2 more sources

Commentary: Three questions for the study of traumatic brain injury in animals

The Anatomical Record, EarlyView.
Gregory Hollin
wiley   +1 more source

Prescribing competence: The pros and cons of different methods for assessment

British Journal of Clinical Pharmacology, EarlyView.
Evaluating a medical graduate’s competence in rational prescribing is challenging. With the aim to guide and inspire teachers, this narrative review explores different methods that can be used to assess prescribing competence. Each method has its own advantages and disadvantages, and thus a mix of different assessment methods is needed throughout the ...
David J. Brinkman, Erik M. Donker, Jelle Tichelaar, on behalf of the CP4T programme   +3 more
wiley   +1 more source

Suitability of the <i>DSM</i>-5 social anxiety disorder severity scale for autistic adults. [PDF]

Autism
Brett SG, den Houting JE, Black MH, Lawson LP, Trollor J, Arnold SR.   +5 more
europepmc   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Social stress task with parental support or self-instruction decreases negative cognitions in children with social anxiety disorder. [PDF]

Sci Rep
Vietmeier N, Tuschen-Caffier B, Asbrand J.   +2 more
europepmc   +1 more source

An open‐label, single‐arm, dose‐escalating concentration–QT study to investigate the cardiac effects and safety of paroxetine in healthy adults

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paroxetine is a selective serotonin reuptake inhibitor (SSRI), approved for treatment of major depressive disorder and anxiety disorders. Some SSRIs are known to prolong the QT interval; however, clinical evidence to establish a lack of association between paroxetine and corrected QT interval (QTc) prolongation is limited. Therefore, this
Sven C. van Dijkman, Mathieu Félices, Bhaskar Pandurangavittal, Sanman Ghorpade, Caroline Easterbrook, Marcin Zabielski, Oscar Della Pasqua   +6 more
wiley   +1 more source

Sitagliptin as a therapeutic approach for social anxiety disorder: the role of DPP4 and NPY in modulating social fear and comorbid depressive-like behavior in mice. [PDF]

Neuropsychopharmacology
Zoicas I, Mühle C, von Hörsten S, Plank AC, Kornhuber J.   +4 more
europepmc   +1 more source

Hypnotic doses of fazamorexant induced less impairment on balance and cognition than zolpidem in healthy younger and elderly individualse

British Journal of Clinical Pharmacology, EarlyView.
Aims Fazamorexant is a dual orexin receptor antagonist being developed for the treatment of insomnia. This study aims to determine the dose‐exposure‐response relationship of single‐dose fazamorexant vs. zolpidem in young adult and elderly healthy Chinese volunteers. Methods This single‐centre, randomized, double‐blind, double‐dummy, placebo‐ and active‐
Chen Xia, Huang Xingxing, Jin Lu, Wang Ruwei   +3 more
wiley   +1 more source

Latent profiles of coping styles and their associations with non-suicidal self-injury in adolescents with social anxiety disorder. [PDF]

Eur Child Adolesc Psychiatry
Ma C, Liu W, Liu Z, Zhang F, Cheng W.
europepmc   +1 more source